N/A N=68 Building and Pilot Testing a Couples-based Smartphone Systems to Address Alcohol Use Disorder
Alcohol Use Disorder · Couples · Behavior, Addictive
Primary: Number of Participants With no Heavy Drinking — 1; 2; 1; 5 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=81 Mobile-Based Contingency Management to Promote Daily Self-monitoring in Primary Care Patients
Pain, Chronic
Primary: Number of Daily Self-monitoring Surveys Completed — 23.06; 26.09 Surveys completed
Phase 3 N=148 Phase 3 Study of OTO-104 in Subjects With Unilateral Meniere's Disease
Meniere Disease
Primary: 28-Day Average DVD at Week 12 (Month 3) — 2.869; 3.577 DVD — p=0.312
Phase 2 N=775 Project 3, Study 2: Extended Exposure to Low Nicotine Content Cigarettes in People With Current Affective Disorders
Tobacco Use Disorder
Primary: Cigarettes Per Day (CPD) — 25.28; 19.95; 17.74 cigarettes per day — p=<0.0001
N/A N=65 Nurse Initiated Acupressure for Pain Management
Pain, Postoperative · Pain, Acute
Primary: Visual Analogue Pain Scale — 3.03; 4.37 units on a scale — p=.048
Phase 4 N=70 Comparing a Virtual vs. Face to Face Weight Management Program Using Phentermine for Patients With Overweight or Obesity
Obesity
Primary: Change in Body Weight (Percentage) — -6.61; -7.68 mean change in body weight (%)
Phase 1 N=32 Phase I Trial of 225Ac-J591 in Patients With mCRPC
Prostate Cancer
Primary: Number of Subjects With Dose Limiting Toxicities (DLT) — 0; 0; 0; 0 Participants
Phase 1 N=24 Bexarotene in Preventing Breast Cancer in Patients at High Risk for Breast Cancer
Breast Atypical Ductal Hyperplasia · Breast Atypical Lobular Hyperplasia · Breast Ductal Carcinoma In Situ
Primary: Number of Participants With Incidence of Adverse Events (Dose Limiting Toxicities) — 0; 1; 1; 0 Participants
N/A N=75 Evaluation of Breast CT
Breast Cancer
Primary: Comparison of Pre- and Post- Contrast Breast Computed Tomography With Pre- and Post- Contrast Magnetic Resonance Imaging. — -0.04 probability — p=0.05
N/A N=30 Low-dose Y90 Treatment Planning for HCC
HCC · Cancer of Liver · Cancer
Primary: Lung Shunt Fraction (LSF) Ratio — 5.68; 5.79 Ratio
Phase 2 N=85 Study to Evaluate Relacorilant (CORT125134) in Combination With Nab-paclitaxel in Participants With Solid Tumors
Solid Tumors
Primary: Number of Participants With Dose-limiting Toxicity — 0; 8; 2; 2 Participants
N/A N=82 Opiate Sparing Versus Opiate Based Following Shoulder Arthroplasty
Shoulder Surgery
Primary: Visual Analog Score (VAS) at Week 2 — 1.4; 1.8 score on a scale
N/A N=73 Metabolic Characteristics of Lean Diabetes in Rural and Semi-urban India and in the United States
Malnutrition; Diabetes · Diabetes
Primary: Endogenous Glucose Production — 0.5; 0.84; 0.6; 0.4 mg/kg/min
Phase 3 N=110 Tdap Vaccine Safety for Plasma Donors
Tetanus
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 71; 42; 0 participants
Phase 2 N=33 Study of Durvalumab and Tremelimumab After Radiation for Microsatellite Stable Metastatic Colorectal Cancer Progressing on Chemotherapy
Colorectal Cancer Metastatic
Primary: Overall Objective Response Rate (ORR) of Dual Immune Checkpoint Blockade by RECIST 1.1 — 9.52 percentage of participants